公开(公告)号：US08455537B2

公开(公告)日：2013-06-04

申请号：US13165431

申请日：2011-06-21

申请人： William J. Welsh ,  Ching Y. Wang ,  Ni Ai

发明人： William J. Welsh ,  Ching Y. Wang ,  Ni Ai

IPC分类号： A61K31/40 ,  A61K31/12 ,  C07C253/00 ,  C07D209/48

CPC分类号： A61K31/4035 ,  A61K31/122 ,  A61K2300/00

摘要： A method for preventing, diagnosing, or treating a condition mediated by an estrogen receptor by administering to a patient in need thereof an effective amount of a compound of formula I, II, or a combination thereof: wherein R1, R3, R4, and R5 are independently selected from H, OH, and ORa; R2 is selected from H, OH, and (C═O) (C1-7)alkyl; Ra is (C1-7)alkyl or (C═O)(C1-7)alkyl; or a derivative of the compound selected from N-oxide derivatives, prodrug derivatives, protected derivatives, isomers, and mixtures of isomers of the compound; or a pharmaceutically acceptable salt or solvate of the compound or the derivative. Compounds of formula I and II and pharmaceuticals compositions thereof are also presented.

摘要翻译： 一种通过向有需要的患者施用有效量的式I，II化合物或其组合来预防，诊断或治疗由雌激素受体介导的病症的方法，其中R1，R3，R4和R5 独立地选自H，OH和ORa; R 2选自H，OH和（C = O）（C 1-7）烷基; R a为（C 1-7）烷基或（C = O）（C 1-7）烷基; 或选自所述化合物的N-氧化物衍生物，前药衍生物，保护的衍生物，异构体和异构体混合物的化合物的衍生物; 或化合物或其衍生物的药学上可接受的盐或溶剂化物。 还提供了式I和II的化合物及其药物组合物。

公开(公告)号：US20110319465A1

公开(公告)日：2011-12-29

申请号：US13165431

申请日：2011-06-21

申请人： William Welsh ,  Ching Y. Wang ,  Ni Ai

发明人： William Welsh ,  Ching Y. Wang ,  Ni Ai

IPC分类号： A61K31/4035 ,  C07D209/48 ,  A61K31/122 ,  A61P19/10 ,  A61P9/10 ,  G01N33/566 ,  A61P43/00 ,  A61P13/08 ,  A61P7/00 ,  A61P15/00 ,  A61P17/00 ,  A61P25/28 ,  C07C49/753 ,  A61P35/00

CPC分类号： A61K31/4035 ,  A61K31/122 ,  A61K2300/00

摘要： A method for preventing, diagnosing, or treating a condition mediated by an estrogen receptor by administering to a patient in need thereof an effective amount of a compound of formula I, II, or a combination thereof: wherein R1, R3, R4, and R5 are independently selected from H, OH, and ORa; R2 is selected from H, OH, and (C═O) (C1-7)alkyl; Ra is (C1-7)alkyl or (C═O)(C1-7)alkyl; or a derivative of the compound selected from N-oxide derivatives, prodrug derivatives, protected derivatives, isomers, and mixtures of isomers of the compound; or a pharmaceutically acceptable salt or solvate of the compound or the derivative. Compounds of formula I and II and pharmaceuticals compositions thereof are also presented.

摘要翻译： 一种通过向有需要的患者施用有效量的式I，II化合物或其组合来预防，诊断或治疗由雌激素受体介导的病症的方法，其中R1，R3，R4和R5 独立地选自H，OH和ORa; R2选自H，OH和（C = O）（C 1-7）烷基; R a为（C 1-7）烷基或（C = O）（C 1-7）烷基; 或选自所述化合物的N-氧化物衍生物，前药衍生物，保护的衍生物，异构体和异构体混合物的化合物的衍生物; 或化合物或其衍生物的药学上可接受的盐或溶剂化物。 还提供了式I和II的化合物及其药物组合物。